T. Kagaya

Functional disorders of the sympathetic nervous system in mice lacking the α1B subunit (Cav 2.2) of N-type calcium channels

Sheryl E. Koch, Y. Mori, T. Nagasu, 2001, Proceedings of the National Academy of Sciences of the United States of America.

A novel truncated glucagon-like peptide 2 (GLP-2) as a tool for analyzing GLP-2 receptor agonists.

J. Nagakawa, H. Terauchi, K. Tsukahara, 2013, Biomedical research.

Species-specific differences in agonistic activity of ago-allosteric modulators toward glucagon-like peptide 2 receptor.

J. Nagakawa, H. Terauchi, K. Tsukahara, 2012, Biomedical research.

Ago-allosteric modulators of human glucagon-like peptide 2 receptor.

J. Nagakawa, H. Terauchi, K. Tsukahara, 2012, Bioorganic & medicinal chemistry letters.

E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A.

A. Kubota, K. Akasaka, T. Kagaya, 1996, The Journal of pharmacology and experimental therapeutics.

Involvement of P-type calcium channels in high potassium-elicited release of neurotransmitters from rat brain slices

T. Watanabe, Y. Yamanishi, T. Hanada, 1995, Neuroscience.

Differential effects of the strychnine-insensitive glycine site antagonist (+)-HA-966 on the hyperactivity and the disruption of prepulse inhibition induced by phencyclidine in rats

H. Ogura, Y. Nishizawa, T. Kagaya, 1998, Brain Research.

Competitive NMDA receptor antagonists disrupt prepulse inhibition without reduction of startle amplitude in a dopamine receptor-independent manner in mice.

H. Ogura, Y. Nishizawa, T. Kagaya, 1999, European journal of pharmacology.

Dopamine D3 agonists disrupt social behavior in rats

M. Yonaga, Y. Nishizawa, T. Kagaya, 1996, Brain Research.